- Conditions
- Diabetic Foot Ulcer, Lower Extremity Wound
- Interventions
- DermACELL AWM
- Other
- Lead sponsor
- LifeNet Health
- Industry
- Eligibility
- 21 Years to 85 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 2
- States / cities
- Fresno, California • Rocky Mount, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1369–1392
of 4,271
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Classic Hodgkin Lymphoma, Lugano Classification Stage III Hodgkin Lymphoma AJCC v8, Lugano Classification Stage IV Hodgkin Lymphoma AJCC v8
- Interventions
- Bleomycin, Dacarbazine, Doxorubicin Hydrochloride, Rituximab, Vinblastine
- Drug · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 17 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2018
- U.S. locations
- 4
- States / cities
- Miami, Florida • Chicago, Illinois • New York, New York + 1 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Placebo, Epratuzumab
- Drug
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 791 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 49
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Hemet, California + 44 more
- Conditions
- Pregnant Women
- Interventions
- Posturography Evaluation, Anthropometrics, Vitals, Health and daily activity questionnaires
- Diagnostic Test · Other
- Lead sponsor
- Caps Research Network
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Marietta, Georgia
- Conditions
- Follicular Lymphoma
- Interventions
- MK-1045, Rituximab, Rituximab biosimilar, Bendamustine, Cyclophosphamide, Vincristine, Prednisone, Prednisolone, Doxorubicin Hydrochloride
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 960 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2035
- U.S. locations
- 7
- States / cities
- Duarte, California • Lexington, Kentucky • Hackensack, New Jersey + 4 more
- Conditions
- Cardiovascular Disease, Diabetes, Obesity, Metabolic Syndrome, Aging
- Interventions
- Not listed
- Lead sponsor
- Tufts University
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Obesity, Body Composition
- Interventions
- Smartwatch activity and body composition monitor, General guidance on recommended exercise
- Device · Behavioral
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Vincristine Placebo, Prednisone, Polatuzumab vedotin Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 49
- States / cities
- Birmingham, Alabama • Daphne, Alabama • Duarte, California + 38 more
- Conditions
- Overweight and Obesity, Attention-Deficit Hyperactivity Disorder
- Interventions
- PBT-EF
- Behavioral
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 8 Years to 12 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Cirrhosis, Hepatic Encephalopathy
- Interventions
- Neurofit (oculometric testing)
- Device
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Redwood City, California
- Conditions
- Bladder Cancer
- Interventions
- keyhole limpet hemocyanin, doxorubicin hydrochloride
- Biological · Drug
- Lead sponsor
- Intracel
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2004
- U.S. locations
- 1
- States / cities
- Frederick, Maryland
- Conditions
- Breast Cancer
- Interventions
- Engagement in Physical Activity, Questionnaires
- Behavioral · Other
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 21 Years to 99 Years · Female only
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Postoperative Delirium, Hemodynamic Instability, Pain, Neurocognitive Dysfunction
- Interventions
- EEG Monitoring, Ropivacaine, Ketamine, Remifentanil, Dexmedetomidine, Rocuronium, Propofol
- Device · Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Prostate Cancer
- Interventions
- doxorubicin hydrochloride, estramustine phosphate sodium, drug resistance inhibition treatment
- Drug · Procedure
- Lead sponsor
- University of New Mexico
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2013
- U.S. locations
- 1
- States / cities
- Albuquerque, New Mexico
- Conditions
- Sarcoma
- Interventions
- filgrastim, doxorubicin hydrochloride, ifosfamide, mesna, vincristine sulfate, conventional surgery, brachytherapy, low-LET cobalt-60 gamma ray therapy, low-LET electron therapy, low-LET photon therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2006
- U.S. locations
- 7
- States / cities
- Wichita, Kansas • New Orleans, Louisiana • Memphis, Tennessee + 4 more
- Conditions
- Substance Related Disorders, Mental Illness
- Interventions
- Maintaining Independence and Sobriety Through Systems Integration, Outreach, and Networking (Veterans Edition), Getting To Outcomes
- Behavioral · Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- Not listed
- Enrollment
- 227 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2016
- U.S. locations
- 4
- States / cities
- Denver, Colorado • Washington D.C., District of Columbia • Bedford, Massachusetts + 1 more
- Conditions
- Perforated Eardrum
- Interventions
- Isoflurane Inhalant Product, Sevoflurane inhalant product, Propofol injection, Remifentanil Injection
- Drug
- Lead sponsor
- Our Lady of the Lake Hospital
- Other
- Eligibility
- 0 Years to 100 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Baton Rouge, Louisiana
- Conditions
- Implicit Bias, Treatment Decisions
- Interventions
- Black Patient race condition, White Patient race condition
- Other
- Lead sponsor
- New York University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Anaplastic Large-Cell Lymphoma, Non-Hodgkin Lymphoma, T-Cell Lymphoma
- Interventions
- brentuximab vedotin, doxorubicin, prednisone, vincristine, cyclophosphamide
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 452 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 32
- States / cities
- Gilbert, Arizona • Duarte, California • Stanford, California + 24 more
- Conditions
- Sarcoma
- Interventions
- filgrastim, carboplatin, cyclophosphamide, dexrazoxane hydrochloride, doxorubicin hydrochloride, etoposide, ifosfamide, irinotecan hydrochloride, vincristine sulfate, conventional surgery, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Up to 50 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Obsessive - Compulsive Disorder
- Interventions
- Repetitive Transcranial Magnetic Stimulation (rTMS), Supportive Therapy (ST), Exposure and Response Prevention (ERP) Therapy
- Device · Behavioral
- Lead sponsor
- Adam Frank
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Breast Neoplasms
- Interventions
- MEDI4736
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Soft Tissue Sarcoma
- Interventions
- Olaratumab, Doxorubicin, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 509 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 30
- States / cities
- Duarte, California • Los Angeles, California • Stanford, California + 20 more
- Conditions
- Insomnia, Mild Cognitive Impairment
- Interventions
- Cognitive Training, Trivia Training
- Behavioral
- Lead sponsor
- University of Missouri-Columbia
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Columbia, Missouri